BCWM
ACAD icon

Bartlett & Co Wealth Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Bartlett & Co Wealth Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-100
Closed -$1.64K – 1098
2022
Q3 		$1.64K Hold
100
– – ﹤0.01% 1070
2022
Q2 		$1.41K Hold
100
– – ﹤0.01% 1218
2022
Q1 		$2.42K Buy
+100
New +$2.42K ﹤0.01% 985

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Bartlett & Co Wealth Management's ACAD Position: Q4 2022 in Review

Bartlett & Co Wealth Management sold out of Acadia Pharmaceuticals (ACAD) in Q4 2022, closing a stake of 100 shares — an estimated $1.64K sold.

Bartlett & Co Wealth Management first reported a position in ACAD in Q1 2022 and held it in 3 quarters. The position peaked at $2.42K in Q1 2022. 227 funds tracked by Wall St. Rank hold ACAD as of Q4 2022.

  • Bartlett & Co Wealth Management reported no remaining Acadia Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Bartlett & Co Wealth Management sold 100 Acadia Pharmaceuticals shares in Q4 2022, an estimated $1.64K.
  • Bartlett & Co Wealth Management first reported a position in Acadia Pharmaceuticals in Q1 2022 and held it in 3 quarters.
  • Bartlett & Co Wealth Management's Acadia Pharmaceuticals position peaked at $2.42K in Q1 2022.
  • 227 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2022.

Based on Bartlett & Co Wealth Management's 13F filing for Q4 2022, filed 14 Feb 2024.